MAPK
As MAPKs são uma família de proteínas quinases envolvidas em uma variedade de processos celulares, incluindo crescimento, proliferação, diferenciação e respostas ao estresse. A via de sinalização MAPK consiste em várias camadas, incluindo ERK, JNK e p38 MAPKs, cada uma desempenhando papéis distintos na função celular. A desregulação da sinalização MAPK está ligada ao câncer, doenças inflamatórias e distúrbios metabólicos. Na CymitQuimica, oferecemos uma ampla gama de inibidores e ativadores de MAPK para apoiar sua pesquisa em biologia celular, transdução de sinais e mecanismos de doenças.
Foram encontrados 885 produtos de "MAPK"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
INCB159020
CAS:<p>INCB159020 is an orally active inhibitor of KRAS G12D, exhibiting a KRAS G12D SPR value of 2.2 nM. It demonstrates anti-tumor activity.</p>Fórmula:C37H35ClFN7O2Cor e Forma:SolidPeso molecular:664.171GDC-6036-NH
CAS:<p>GDC-6036-NH is a precursor of compound 17a /b, which is a RAS inhibitor that can be used in cancer research.</p>Fórmula:C26H30ClF4N7OPureza:99.84%Cor e Forma:SolidPeso molecular:568.01JH295 hydrate
<p>JH295 hydrate: potent, irreversible Nek2 inhibitor (IC50 = 770 nM), selective, doesn't target Cdk1, Aurora B or Plk1.</p>Fórmula:C18H18N4O3Cor e Forma:SolidPeso molecular:338.36KRAS inhibitor-13
CAS:<p>KRAS inhibitor-13 blocks KRAS G12C (IC50: 0.883 μM) and p-ERK in some cancer cells; promising for pancreatic, colorectal, lung cancer research.</p>Fórmula:C25H19ClFN3O2SCor e Forma:SolidPeso molecular:479.95JD118
CAS:<p>JD118 is an inhibitor of JNK. It effectively suppresses the activity of JNK1 and the expression of cJun (1 - 135).</p>Fórmula:C13H12N4S2Cor e Forma:SolidPeso molecular:288.391AMG-548 hydrochloride
<p>AMG-548 hydrochloride: orally active, p38α inhibitor (Ki=0.5 nM), 1000x less for p38γ/δ, also blocks TNFα (IC50=3 nM) & inhibits casein kinase 1 δ/ε.</p>Fórmula:C29H28ClN5OCor e Forma:SolidPeso molecular:498.02HPK1-IN-42
CAS:HPK1-IN-42 (compound 185) is an inhibitor of HPK1, displaying potent activity with an IC50 of 0.24 nM [1].Fórmula:C26H30N6OSCor e Forma:SolidPeso molecular:474.62SHR902275
CAS:<p>SHR902275: potent RAF inhibitor, hits RAS mutations, oral use. cRAF IC50=1.6 nM, bRAFwt IC50=10 nM, bRAFV600E IC50=5.7 nM, hinders cell growth.</p>Fórmula:C26H23F3N4O4Cor e Forma:SolidPeso molecular:512.48KRAS inhibitor-35
CAS:<p>KRAS inhibitor-35 (compound 72) is a KRAS inhibitor with an IC50 of 2 nM, utilized in tumor research.</p>Fórmula:C38H32F4N6O3SCor e Forma:SolidPeso molecular:728.76Anti-osteoporosis agent-11
CAS:<p>Anti-osteoporosis agent-11 (compound 3k) is an anti-osteoporosis compound targeting osteoclasts. It exhibits its most prominent effect by inhibiting osteoclast differentiation, with an IC50 value of 0.36 μM. Additionally, Anti-osteoporosis agent-11 suppresses osteoclast formation, bone resorption, and the expression of osteoclast-specific genes by blocking the RANKL-induced mitogen-activated protein kinase (MAPK) and NF-κB signaling pathways.</p>Fórmula:C23H17NO2Se2Cor e Forma:SolidPeso molecular:497.31ERK1/2 inhibitor 6
CAS:<p>ERK1/2 inhibitor 6 - potent cancer/inflammation treatment from WO2021063335A1.</p>Fórmula:C27H29ClFN7O5Cor e Forma:SolidPeso molecular:586.01RSK4-IN-1
CAS:<p>RSK4-IN-1 is a compound exhibiting potent inhibition of RSK4, demonstrated by an IC50 value of 9.5 nM.</p>Fórmula:C19H20F2N4O3Cor e Forma:SolidPeso molecular:390.38Refametinib R enantiomer
CAS:<p>Refametinib R enantiomer (RDEA119 R enantiomer) is an MEK inhibitor with an EC50 of 2.0-15 nM.Refametinib (R enantiomer) has anticancer activity and can be used</p>Fórmula:C19H20F3IN2O5SPureza:99.86%Cor e Forma:SolidPeso molecular:572.34JNK-1-IN-5
CAS:<p>JNK-1-IN-5 (Compound 14) is a potent JNK1 inhibitor with sub-nanomolar efficacy. It effectively inhibits TGF-β-induced epithelial-mesenchymal transition and shows promise for research targeting JNK1 as an anti-pulmonary fibrosis agent.</p>Fórmula:C23H21BrN6O3Cor e Forma:SolidPeso molecular:509.355HPK1-IN-3
<p>HPK1-IN-3: Selective HPK1 inhibitor, ATP-competitive, IC50=0.25nM; boosts IL-2 in PBMCs, EC50=108nM.</p>Fórmula:C23H22F4N6O2Cor e Forma:SolidPeso molecular:490.45SOS1-IN-9
<p>SOS1-IN-9 is a potent inhibitor of SOS1 that acts on KRAS G12C-SOS1 (IC50: 116.5 nM).</p>Fórmula:C22H28F3N5OCor e Forma:SolidPeso molecular:435.49KRAS inhibitor-41
CAS:<p>KRAS inhibitor-41 is a KRAS inhibitor with an IC50 value of less than 0.01 μM for both KRAS G12D and KRAS G12V mutations. It effectively inhibits RAS mutant cell lines GP2D (KRAS-G12D) and SW620 (KRAS-G12V). KRAS inhibitor-41 is applicable for cancer research.</p>Fórmula:C30H37FN10OSCor e Forma:SolidPeso molecular:604.745KRAS G12C inhibitor 44
<p>KRAS G12C inhibitor 44: potent, oral, anti-cancer; halts cell growth in MIA PaCA-2, H358; effective in vivo. IC50: MIA-0.016μM, H358-0.028μM.</p>Fórmula:C31H36ClFN6O2Cor e Forma:SolidPeso molecular:579.11Rho GTPase inhibitor 1
CAS:<p>Rho GTPase inhibitor 1 (compound 7) is a potent inhibitor of Rho GTPase. It exhibits high affinity for Cdc42, Rac1, and RhoA, with dissociation constants (KDs) of 151 μM, 352 μM, and 232 μM, respectively. Additionally, Rho GTPase inhibitor 1 reduces cell migration in glioblastoma cell lines.</p>Fórmula:C18H16N2OCor e Forma:SolidPeso molecular:276.33G-479
CAS:<p>G-479, a potent MEK inhibitor and improved analogue of GDC-0623, has distributed polarity enhancing bioactivity.</p>Fórmula:C16H15FIN5O4Cor e Forma:SolidPeso molecular:487.22
